pulmatrix pipeline

The Company has built an impressive package of pre-clinical data demonstrating treatment efficacy, prophylaxis, and transmission control in multiple animal species, in both viral and bacterial diseases as well as reduced inflammation in acute models of lung injury caused by tobacco smoke and allergic asthma.

Pulmatrix is developing a broad pipeline to prevent and treat a range of respiratory diseases which have considerable unmet medical need. Disease applications for iCALM include chronic respiratory diseases such as COPD, asthma, and cystic fibrosis, as well as respiratory infections such as influenza, ILI, rhinovirus, VAP, and RSV in both compromised and healthy individuals.